Cantor Fitzgerald Initiates Coverage On BridgeBio Pharma with Overweight Rating, Announces Price Target of $50
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Josh Schimmer has initiated coverage on BridgeBio Pharma (NASDAQ:BBIO) with an Overweight rating and a price target of $50.
October 24, 2023 | 9:01 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BridgeBio Pharma has been given an Overweight rating and a price target of $50 by Cantor Fitzgerald.
The Overweight rating from Cantor Fitzgerald indicates a positive outlook for BridgeBio Pharma. The price target of $50 suggests that the analyst believes the stock has significant upside potential. This could lead to increased investor interest and a potential rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100